Neurology Minute Lab Minutes - Paraneoplastic Lab
Jan 8, 2025
Dr. Stacey Clardy dives into the complex world of paraneoplastic panels. She urges caution, highlighting how routine panel use often overlooks non-cancer-associated antibodies. For a more effective neurological assessment, she advocates incorporating autoimmune encephalopathy panels. This shift could lead to better evaluations and outcomes for patients.
AI Snips
Chapters
Transcript
Episode notes
Avoid Paraneoplastic Panels
- Avoid ordering a so-called paraneoplastic panel.
- These panels are often ordered mistakenly and give incomplete results.
Paraneoplastic Panel Contents
- Paraneoplastic panels primarily include antibodies highly associated with cancer (e.g., anti-HU, anti-YO, anti-RI).
- They often omit antibodies like NMDAR, LGI-1, or GAD-65, which are common in autoimmune neurological syndromes.
When to Consider Paraneoplastic Panels
- Consider a paraneoplastic panel for specific cancer types with neurological symptoms, like small cell lung cancer with neuronopathy.
- A phenotype-specific panel offers a broader assessment, including both paraneoplastic and non-paraneoplastic antibodies.